Skip to main content
Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity

Fig. 6

NK cells from laquinimod-treated mice inhibit autoreactive T cell proliferation by interacting with CD155+ DCs. a Representative CFSE profiles of 2D2 T cells stimulated by bmDCs and MOG35–55 in the presence of sorted NK cells from laquinimod- or vehicle-treated animals. Numbers in the left top quadrant indicate the percentage of non-proliferating T cells. b Graph quantifying the CSFE profiles of a. Data are presented as mean ± S.E.M. of two pooled independent experiments. *P < 0.05, Kruskal Wallis test with Dunn’s post-test. c Graph depicting the percentage of non-proliferating 2D2 T cells as assessed by CFSE staining if NK cells were separated by a transwell from 2D2 T cells and DCs. Data are presented as mean ± S.E.M. of three pooled independent experiments. *P < 0.05, ***P < 0.001, one-way ANOVA with Bonferroni post-test. d Representative flow cytometry plots showing the Annexin V/7-AAD staining of DCs in co-culture experiments with sorted splenic NK cells from laquinimod- or vehicle-treated mice, quantified in e. Data are presented as mean ± S.E.M. of two pooled independent experiments. ***P < 0.001, one-way ANOVA with Bonferroni post-test. f Quantification of the percentage of non-proliferating 2D2 T cells as assessed by CFSE labeling in co-cultures with CD155 deficient or wild-type DCs, MOG35–55, and splenic NK cells sorted from laquinimod- or vehicle-treated mice. Data are presented as mean ± S.E.M. and are pooled from three independent experiments. **P < 0.01, unpaired t test. g MHC class II expression (median FI) of bone marrow-derived DCs cultured in the presence of DNAM-1 Fc chimeric proteins or control IgG as assessed by flow cytometry. *P < 0.05, ***P < 0.001, one-way ANOVA with Dunnett’s post-test

Back to article page